Drug Design At The Peroxisome ProliferatorActivated Receptor,Used

Drug Design At The Peroxisome ProliferatorActivated Receptor,Used

In Stock
SKU: DADAX3659255785
Brand: LAP Lambert Academic Publishing
$113.92 $162.74
Save $48.82
Quantity
Add to wishlist
Add to compare

Processing time: 1-3 days

US Orders Ships in: 3-5 days

International Orders Ships in: 8-12 days

Return Policy: 15-days return on defective items

Payment Option
Payment Methods

Help

If you have any questions, you are always welcome to contact us. We'll get back to you as soon as possible, withing 24 hours on weekdays.

Customer service

All questions about your order, return and delivery must be sent to our customer service team by e-mail at yourstore@yourdomain.com

Sale & Press

If you are interested in selling our products, need more information about our brand or wish to make a collaboration, please contact us at press@yourdomain.com

The Peroxisome ProliferatorActivated Receptor Gamma (PPAR?) agonist Rosiglitazone, has recently been withdrawn from the European market and its use has been restricted in the US due to its undesirable effects which were considered to outweigh its benefits. This study explores the two agonist bound conformations of the PPAR?, as exemplified by its binding to Rosiglitazone and that to Farglitazar. Furthermore, it evaluates whether they should be targeted separately in the context of drug design studies. The binding modalities of Rosiglitazone and Farglitazar were studied in great detail and a series of molecules capable of agonist activity at the PPAR? have been designed, with the potential to act as leads in a drug design process.

⚠️ WARNING (California Proposition 65):

This product may contain chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.

For more information, please visit www.P65Warnings.ca.gov.

Recently Viewed